Metabolism of tricyclic antidepressants

被引:90
作者
Rudorfer, MV
Potter, WZ
机构
[1] NIMH, Div Serv & Intervent Res, Bethesda, MD 20892 USA
[2] Lilly Res Labs, Indianapolis, IN USA
关键词
antidepressants; tricyclic; metabolism; hydroxy metabolites; pharmacokinetics; pharmacogenetics; drug-drug interactions; toxicity; plasma concentrations;
D O I
10.1023/A:1006949816036
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
1. Despite the considerable advances in the treatments available for mood disorders over the past generation, tricyclic antidepressants TCAs remain an important option for the pharmacotherapy of depression. 2. The pharmacokinetics of TCAs are characterized by substantial presystemic firstpass metabolism, a large volume of distribution, extensive protein binding, and an elimination half-life averaging about 1 day (up to 3 days for protriptyline). 3. Clearance of tricyclics is dependent primarily on hepatic cytochrome P450 (CYP) oxidative enzymes. Although the activities of some P450 isoenzymes are largely under genetic control, they may be influenced by external factors, such as the concomitant use of other medications or substances. Patient variables, such as ethnicity and age, also affect TCA metabolism. The impact of gender and related reproductive issues is coming under increased scrutiny. 4. Metabolism of TCAs, especially their hydroxylation, results in the formation of active metabolites, which contribute to both the therapeutic and the adverse effects of these compounds. 5. Renal clearance of the polar metabolites of TGAs is reduced by normal aging, accounting for much of the increased risk of toxicity in older patients. 6. Knowledge of factors affecting the metabolism of TCAs can further the development and understanding of newer antidepressant medications.
引用
收藏
页码:373 / 409
页数:37
相关论文
共 203 条
[11]   CLINICAL PHARMACOKINETICS OF CLOMIPRAMINE [J].
BALANTGORGIA, AE ;
GEXFABRY, M ;
BALANT, LP .
CLINICAL PHARMACOKINETICS, 1991, 20 (06) :447-462
[12]   A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache [J].
Bendtsen, L ;
Jensen, R ;
Olesen, J .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 61 (03) :285-290
[13]   NEONATAL EFFECTS OF MATERNAL CLOMIPRAMINE THERAPY [J].
BENMUSA, A ;
SMITH, CS .
ARCHIVES OF DISEASE IN CHILDHOOD, 1979, 54 (05) :405-405
[14]   QUANTIFICATION AND MECHANISM OF THE FLUOXETINE AND TRICYCLIC ANTIDEPRESSANT INTERACTION [J].
BERGSTROM, RF ;
PEYTON, AL ;
LEMBERGER, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (03) :239-248
[15]   PRONOUNCED INHIBITION OF NORADRENALINE UPTAKE BY 10-HYDROXY-METABOLITES OF NORTRIPTYLINE [J].
BERTILSSON, L ;
MELLSTROM, B ;
SJOQVIST, F .
LIFE SCIENCES, 1979, 25 (15) :1285-1292
[16]   EXTREMELY RAPID HYDROXYLATION OF DEBRISOQUINE - A CASE-REPORT WITH IMPLICATION FOR TREATMENT WITH NORTRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANTS [J].
BERTILSSON, L ;
ABERGWISTEDT, A ;
GUSTAFSSON, LL ;
NORDIN, C .
THERAPEUTIC DRUG MONITORING, 1985, 7 (04) :478-480
[17]   Polymorphic drug oxidation - Relevance to the treatment of psychiatric disorders [J].
Bertilsson, L ;
Dahl, ML .
CNS DRUGS, 1996, 5 (03) :200-223
[18]   DISPOSITION OF SINGLE ORAL DOSES OF E-10-HYDROXYNORTRIPTYLINE IN HEALTHY-SUBJECTS, WITH SOME OBSERVATIONS ON PHARMACODYNAMIC EFFECTS [J].
BERTILSSON, L ;
NORDIN, C ;
OTANI, K ;
RESUL, B ;
SCHEININ, M ;
SIWERS, B ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (03) :261-267
[19]  
BERTILSSON L, 1989, CLIN PHARM PSYCHIAT, P52
[20]   Cerebral metabolism of imipramine and a purified flavin-containing monooxygenase from human brain [J].
Bhagwat, SV ;
Bhamre, S ;
Boyd, MR ;
Ravindranath, V .
NEUROPSYCHOPHARMACOLOGY, 1996, 15 (02) :133-142